Melinda L Jackson1,2, R Doug McEvoy3, Siobhan Banks4, Maree Barnes1,5. 1. Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia. 2. School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia. 3. Adelaide Institute for Sleep Health: Flinders Centre of Research Excellence Flinders University, Bedford Park, South Australia, Australia. 4. Centre for Sleep Research, University of South Australia, Adelaide, Australia. 5. Department of Medicine, The University of Melbourne, Victoria, Australia.
Abstract
STUDY OBJECTIVES: The degree of neurobehavioral impairment and treatment response in mild-moderate obstructive sleep apnea (OSA) compared to that of an appropriate control group are unclear. This study compared neurobehavioral function and response to continuous positive airway pressure (CPAP) treatment in patients with mild to moderate OSA with those of a non-sleep apneic community sample of similar demography. METHODS: One hundred ten patients with OSA and 31 asymptomatic community dwellers underwent overnight polysomnography and neurobehavioral testing. Participants with OSA (n = 88) were treated with CPAP for 3 months, and repeat evaluations were performed at the end of the treatment period. RESULTS: Compared to the community sample, participants with OSA were significantly sleepier, had impaired mood and quality of life, and showed decrements in neuropsychological function, specifically psychomotor function, working memory and vigilance. Some neuropsychological and mood outcomes were normalized with CPAP, but significant decrements persisted in most outcomes even in those participants with adequate device usage. CONCLUSIONS: Patients with mild to moderate OSA have significant neurobehavioral morbidity. During "gold standard" treatment, normal function was not achieved, even with adequate device usage. CPAP efficacy for improving sleepiness and neuropsychological function in this milder end of the OSA spectrum may be poor, which may affect CPAP adherence. These findings suggest that there may be neurological changes related to OSA that do not respond to CPAP treatment, the etiology of which requires further investigation.
STUDY OBJECTIVES: The degree of neurobehavioral impairment and treatment response in mild-moderate obstructive sleep apnea (OSA) compared to that of an appropriate control group are unclear. This study compared neurobehavioral function and response to continuous positive airway pressure (CPAP) treatment in patients with mild to moderate OSA with those of a non-sleep apneic community sample of similar demography. METHODS: One hundred ten patients with OSA and 31 asymptomatic community dwellers underwent overnight polysomnography and neurobehavioral testing. Participants with OSA (n = 88) were treated with CPAP for 3 months, and repeat evaluations were performed at the end of the treatment period. RESULTS: Compared to the community sample, participants with OSA were significantly sleepier, had impaired mood and quality of life, and showed decrements in neuropsychological function, specifically psychomotor function, working memory and vigilance. Some neuropsychological and mood outcomes were normalized with CPAP, but significant decrements persisted in most outcomes even in those participants with adequate device usage. CONCLUSIONS:Patients with mild to moderate OSA have significant neurobehavioral morbidity. During "gold standard" treatment, normal function was not achieved, even with adequate device usage. CPAP efficacy for improving sleepiness and neuropsychological function in this milder end of the OSA spectrum may be poor, which may affect CPAP adherence. These findings suggest that there may be neurological changes related to OSA that do not respond to CPAP treatment, the etiology of which requires further investigation.
Authors: M J Morrell; M L Jackson; G L Twigg; R Ghiassi; D W McRobbie; R A Quest; H Pardoe; G S Pell; D F Abbott; P D Rochford; G D Jackson; R J Pierce; F J O'Donoghue; D R Corfield Journal: Thorax Date: 2010-10 Impact factor: 9.139
Authors: Yasaman Djavadkhani; Nathaniel S Marshall; Angela L D'Rozario; Megan R Crawford; Brendon J Yee; Ronald R Grunstein; Craig L Phillips Journal: Thorax Date: 2015-01-16 Impact factor: 9.139
Authors: Ana Isabel Sánchez; Pilar Martínez; Elena Miró; Wayne A Bardwell; Gualberto Buela-Casal Journal: Sleep Med Rev Date: 2009-02-07 Impact factor: 11.609
Authors: Maree Barnes; R Douglas McEvoy; Siobhan Banks; Natalie Tarquinio; Christopher G Murray; Norman Vowles; Robert J Pierce Journal: Am J Respir Crit Care Med Date: 2004-06-16 Impact factor: 21.405
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Anna E Mullins; Korey Kam; Ankit Parekh; Omonigho M Bubu; Ricardo S Osorio; Andrew W Varga Journal: Neurobiol Dis Date: 2020-08-27 Impact factor: 5.996
Authors: David F Smith; Kathleen M Sarber; Charlene P Spiceland; Stacey L Ishman; Dianne M Augelli; Ann M Romaker Journal: J Clin Sleep Med Date: 2019-07-15 Impact factor: 4.062
Authors: Ina E Djonlagic; Meng Guo; Moroke Igue; Divya Kishore; Robert Stickgold; Atul Malhotra Journal: Am J Respir Crit Care Med Date: 2021-05-01 Impact factor: 21.405
Authors: Almudena Carneiro-Barrera; Francisco J Amaro-Gahete; Germán Sáez-Roca; Carlos Martín-Carrasco; Jonatan R Ruiz; Gualberto Buela-Casal Journal: J Clin Med Date: 2019-12-01 Impact factor: 4.241